Naglazyme and Spinal decompression - a phase IV clinical study of FDA data

Summary:

Spinal decompression is reported as a side effect among people who take Naglazyme (galsulfase), especially for people who are male, 10-19 old,.

The phase IV clinical study analyzes which people have Spinal decompression when taking Naglazyme. It is created by eHealthMe based on reports of 3,919 people who have side effects when taking Naglazyme from the FDA, and is updated regularly.

What is Naglazyme?

Naglazyme has active ingredients of galsulfase. eHealthMe is studying from 3,922 Naglazyme users. Check the latest studies of Naglazyme.

What is Spinal decompression?

Spinal decompression (relief of pressure on one or many pinched nerves (neural impingement) of the spinal column) is found to be associated with 138 drugs and 141 conditions by eHealthMe. Check the latest studies of Spinal decompression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

3,919 people reported to have side effects when taking Naglazyme.
Among them, 21 people (0.54%) have Spinal decompression.

Could Naglazyme cause Spinal decompression?

Among these 21 people:

What is the gender of people who have Spinal decompression when taking Naglazyme? *

female: 35.29 %
male: 64.71 %

What is the age of people who have Spinal decompression when taking Naglazyme? *

What are other side effects people have besides Spinal decompression? *

Spinal Pain (pain in spine): 2 people, 9.52%
Atelectasis (partial or complete collapse of the lung): 2 people, 9.52%
Post Procedural Complication: 2 people, 9.52%
Pneumonia: 2 people, 9.52%
Drug Ineffective: 2 people, 9.52%
Paranasal Sinus Hypersecretion: 2 people, 9.52%
Pain: 2 people, 9.52%
Dyskinesia (abnormality or impairment of voluntary movement): 2 people, 9.52%
Insomnia (sleeplessness): 2 people, 9.52%
Lung Consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces): 2 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Naglazyme and have Spinal decompression?

- Check whether Spinal decompression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Naglazyme:

Naglazyme (3,922 reports)

Browse all side effects of Naglazyme:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Spinal decompression:

Spinal decompression (138 drugs)

Browse all the conditions that are associated with Spinal decompression:

Spinal decompression (141 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on galsulfase (the active ingredients of Naglazyme) and Naglazyme (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.